WALTHAM, Mass • 2023-12-20

BostonGene Announces Publication in Blood

5 min to read

An AI-driven imaging pipeline revolutionizes bone marrow analysis, unraveling the intricacies of hematopoiesis
WALTHAM, Mass – December 20, 2023 — BostonGene, a leading provider of AI-based molecular and immune profiling solutions today announced the online publication of the manuscript, “Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling,” in Blood, the most cited peer-reviewed publication in the field of hematology.

In a recent collaboration, Sanjay Patel, MD, MPH, Assistant Professor of Pathology and Laboratory Medicine and Director of the Multiparametric In Situ Imaging Laboratory at Weill Cornell Medicine, collaborated with BostonGene to investigate how we look at bone marrow. Historically, limited imaging studies have been performed on bone marrow tissue due to sample heterogeneity and complex analytics. To address these challenges, the study team developed an AI-driven multiparametric end-to-end imaging pipeline, encompassing whole tissue staining, whole slide in situ imaging, and integrative image analysis. This pipeline was applied to normal clinical samples to survey changes in the topography of human hematopoiesis associated with aging, uncovering intricate relationships among the 1.5 million cells analyzed across 11 unique cell types. The study findings not only expands our understanding of bone marrow dynamics but also paves the way for future innovations in the diagnosis and treatment of blood-based diseases.

Dr. Patel emphasized the clinical significance of this innovative approach, stating, “Our versatile pipeline for multiparametric imaging and analysis of human bone marrow can allow any user to manage an unwieldy amount of data. In this proof-of-concept study we demonstrate the utility of this pipeline in revealing subtle changes in the hematopoietic topography associated with aging.”

“This adaptable pipeline can be harnessed by other investigators pursuing single-cell resolution spatial investigation of bone marrow,” added Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our pipeline not only enhances our understanding of normal bone marrow but also has implications for novel diagnostic and therapeutic approaches in precision oncology, particularly for blood-based cancers.”

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director